Details of the Drug

General Information of Drug (ID: DM8VCBE)

Drug Name

Ibuprofen

Synonyms

ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid; Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1], [2]

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

206.28

Topological Polar Surface Area (xlogp)

3.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 70 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 20 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 85% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The clearance of drug is 3-13 L/h [6]
Elimination: Ibuprofen is rapidly metabolized and eliminated in the urine thus, this via accounts for more than 90% of the administered dose [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.2 - 2 hours [3]
Metabolism: The drug is metabolized via the liver [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 193.9044 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.006% [8]
Vd: The volume of distribution (Vd) of drug is 0.1 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 0.038 mg/mL [4]

Chemical Identifiers

Formula: C13H18O2
IUPAC Name: 2-[4-(2-methylpropyl)phenyl]propanoic acid
Canonical SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
InChI: InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
InChIKey: HEFNNWSXXWATRW-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3672
ChEBI ID: CHEBI:5855
CAS Number: 15687-27-1
DrugBank ID: DB01050
TTD ID: D0R1QE
VARIDT ID: DR00663
INTEDE ID: DR0844
ACDINA ID: D00320

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Inhibitor	[10]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[10]
Interleukin-8 (IL8)	TTCTE1G	IL8_HUMAN	Inhibitor	[11]
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[12], [13], [14]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Probable small intestine urate exporter (SLC17A4)	DTHE530	S17A4_HUMAN	Substrate	[15]
Monocarboxylate transporter 2 (SLC16A7)	DTLT3UG	MOT2_HUMAN	Substrate	[16]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[17]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[18]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[18]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[19]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[20]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[20]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[20]
Acyl-CoA thioesterase 2 (ACOT2)	DEMEPVJ	ACOT2_HUMAN	Substrate	[21]
Alpha-methylacyl-CoA racemase (AMACR)	DEGKWJB	AMACR_HUMAN	Substrate	[22]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Pain

ICD Disease Classification

MG30-MG3Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	7.93E-04	-0.29	-0.34
Monocarboxylate transporter 2 (SLC16A7)	DTP	MCT2	9.19E-03	-3.31E-01	-5.56E-01
Probable small intestine urate exporter (SLC17A4)	DTP	SLC17A4	8.94E-01	-9.82E-03	-6.82E-02
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.82E-04	-1.35E-01	-5.84E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Alpha-methylacyl-CoA racemase (AMACR)	DME	AMACR	9.28E-01	-1.12E-02	-5.32E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ibuprofen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[94]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Ibuprofen and Glipizide.	Acute diabete complication [5A2Y]	[95]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Ibuprofen caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[96]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Inotersen.	Amyloidosis [5D00]	[96]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Cilostazol.	Arterial occlusive disease [BD40]	[97]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Budesonide.	Asthma [CA23]	[98]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[99]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Kanamycin.	Bacterial infection [1A00-1C4Z]	[100]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[99]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Streptomycin.	Bacterial infection [1A00-1C4Z]	[100]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[99]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[99]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Ibuprofen and ABT-492.	Bacterial infection [1A00-1C4Z]	[99]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Ibuprofen and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[99]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Etidronic acid.	Bone paget disease [FB85]	[101]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[102]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Ibuprofen caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[103]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[97]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Iodipamide.	Cholelithiasis [DC11]	[104]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Levomilnacipran.	Chronic pain [MG30]	[105]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Ibuprofen and Regorafenib.	Colorectal cancer [2B91]	[96]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Ibuprofen and Drospirenone.	Contraceptive management [QA21]	[106]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Ibuprofen and Ardeparin.	Coronary thrombosis [BA43]	[107]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Ibuprofen caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[108]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Ibuprofen caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[109]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Ibuprofen caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[110]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Ibuprofen and Danaparoid.	Deep vein thrombosis [BD71]	[107]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Ibuprofen and Rivaroxaban.	Deep vein thrombosis [BD71]	[111]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Sertraline.	Depression [6A70-6A7Z]	[105]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Vilazodone.	Depression [6A70-6A7Z]	[105]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Vortioxetine.	Depression [6A70-6A7Z]	[105]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Milnacipran.	Depression [6A70-6A7Z]	[105]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Desvenlafaxine.	Depression [6A70-6A7Z]	[105]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Clomipramine.	Depression [6A70-6A7Z]	[105]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Cannabidiol.	Epileptic encephalopathy [8A62]	[96]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Tazemetostat.	Follicular lymphoma [2A80]	[97]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Ibuprofen and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[96]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Sulfinpyrazone.	Gout [FA25]	[97]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Ibuprofen caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[112]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[113]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Ibuprofen caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[114]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[115]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[116]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[117]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Ibuprofen caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[94]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Idelalisib.	Mature B-cell leukaemia [2A82]	[118]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Ibuprofen and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[119]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Ibuprofen and Ibrutinib.	Mature B-cell lymphoma [2A85]	[120]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Ibuprofen and Ponatinib.	Mature B-cell lymphoma [2A85]	[121]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Ibuprofen caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[96]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Exjade.	Mineral absorption/transport disorder [5C64]	[122]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Ibuprofen and Panobinostat.	Multiple myeloma [2A83]	[94]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Deflazacort.	Muscular dystrophy [8C70]	[98]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[97]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Ibuprofen and Dasatinib.	Myeloproliferative neoplasm [2A20]	[123]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Ibuprofen and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[124]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Ibuprofen and Prasugrel.	Myocardial infarction [BA41-BA43]	[96]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Sibutramine.	Obesity [5B80-5B81]	[105]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Dexfenfluramine.	Obesity [5B80-5B81]	[105]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Ibuprofen when combined with Polythiazide.	Oedema [MG29]	[125]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Ibuprofen caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[126]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Ibuprofen and MK-4827.	Ovarian cancer [2C73]	[96]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Ibuprofen caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[127]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Epoprostenol.	Pulmonary hypertension [BB01]	[128]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Iloprost.	Pulmonary hypertension [BB01]	[128]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Everolimus.	Renal cell carcinoma [2C90]	[129]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Ibuprofen and Temsirolimus.	Renal cell carcinoma [2C90]	[129]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Dexamethasone.	Rheumatoid arthritis [FA20]	[98]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Ibuprofen and Leflunomide.	Rheumatoid arthritis [FA20]	[116]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Ibuprofen and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[96]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Ibuprofen and Pitolisant.	Somnolence [MG42]	[96]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Caplacizumab.	Thrombocytopenia [3B64]	[97]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Ibuprofen and Apixaban.	Thrombosis [DB61-GB90]	[96]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Cangrelor.	Thrombosis [DB61-GB90]	[97]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Ibuprofen and Brilinta.	Thrombosis [DB61-GB90]	[96]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Ibuprofen and Cabozantinib.	Thyroid cancer [2D10]	[130]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Ibuprofen and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[95]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Olsalazine.	Ulcerative colitis [DD71]	[131]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Ibuprofen and Plazomicin.	Urinary tract infection [GC08]	[100]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Ibuprofen and Betrixaban.	Venous thromboembolism [BD72]	[132]
-----------


⏷ Show the Full List of 80 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Allura red AC dye	E00338	33258	Colorant
Aspartame	E00402	134601	Flavoring agent
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben	E00149	7456	Antimicrobial preservative
Monoammonium glycyrrhizate	E00352	62074	Emulsifying agent; Flavoring agent
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Propyl gallate	E00075	4947	Antimicrobial preservative; Antioxidant
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sorbitol monooleate	E00497	6436309	Emollient; Emulsifying agent; Surfactant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Succinic acid	E00044	1110	Buffering agent
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Caramel	E00350	61634	Colorant; Flavoring agent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dextrose monohydrate	E00538	22814120	Binding agent; Diluent; Flavoring agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Elemental iron	E00280	23925	Other agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Ferrous oxide	E00241	14945	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Kaolin	E00586	56841936	Adsorbent; Diluent; Suspending agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 2000	E00649	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 300	E00651	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbitan monooleate	E00503	9920342	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 67 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ibuprofen 100 mg tablet	100 mg	Chewable Tablet	Oral
Ibuprofen 200 mg tablet	200 mg	Oral Tablet	Oral
Ibuprofen 100 mg tablet	100 mg	Oral Tablet	Oral
Ibuprofen 400 mg tablet	400 mg	Oral Tablet	Oral
Ibuprofen 600 mg tablet	600 mg	Oral Tablet	Oral
Ibuprofen 800 mg tablet	800 mg	Oral Tablet	Oral
Ibuprofen 200 mg capsule	200 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2713).
2	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
3	An overview of clinical pharmacology of Ibuprofen. Oman Med J. 2010 Jul;25(3):155-1661. doi: 10.5001/omj.2010.49.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Rainsford KD: Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342. doi: 10.1007/s10787-009-0016-x. Epub 2009 Nov 21.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Rao P, Knaus EE: Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008 Sep 20;11(2):81s-110s.
10	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
11	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
12	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
13	The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposur... J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32.
14	Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence. Anal Biochem. 1998 Nov 15;264(2):216-21.
15	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
16	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
17	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
18	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
19	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	A study on the chiral inversion of mandelic acid in humans. Org Biomol Chem. 2014 Sep 14;12(34):6737-44.
22	Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342.
23	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
24	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
25	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
26	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
27	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
28	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
29	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
30	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
31	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
32	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
33	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
34	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
35	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
36	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
37	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
38	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
39	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
40	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
41	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
42	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
43	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
44	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
45	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
46	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
47	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
48	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
49	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
50	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
51	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
52	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
53	Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
54	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
55	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
56	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
57	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
58	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
59	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
60	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
61	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
62	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
63	Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
64	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
65	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
66	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
67	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
68	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
69	Alpha-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013 Apr;52(2):220-30.
70	Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clin Transl Sci. 2018 Jul;11(4):352-364.
71	Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35.
72	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
73	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
74	Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34.
75	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240.
76	Company report (Genmab)
77	Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
78	CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
79	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
80	Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
81	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
82	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
83	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
84	Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589.
85	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
86	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
87	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
88	Pfizer. Product Development Pipeline. March 31 2009.
89	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
90	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
91	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
92	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
93	Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
94	Cerner Multum, Inc. "Australian Product Information.".
95	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
96	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
97	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
98	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
99	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
100	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
101	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
102	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
103	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
104	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
105	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
106	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
107	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
108	Cerner Multum, Inc. "Canadian Product Information.".
109	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
110	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
111	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
112	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
113	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
114	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
115	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
116	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
117	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
118	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
119	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
120	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
121	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
122	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
123	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
124	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
125	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
126	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
127	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
128	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
129	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
130	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
131	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
132	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.